Subcutaneous Lecanemab: Potential Benefits and Place in Therapy

Weekly subcutaneous lecanemab has the potential for a prominent place in therapy by providing comparable efficacy relative to intravenous formulation with a more convenient and accessible administration by patients, caregivers or HCPs.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70859_104695
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Subcutaneous Lecanemab: Potential Benefits and Place in Therapy

Erica Andreozzi, Steven M. Hersch, Michelle Gee, Lynn D. Kramer et al.
Alzheimer s & Dementia
Alzheimer's disease research and treatments
article

Subcutaneous Lecanemab: Potential Benefits and Place in Therapy

Erica Andreozzi, Steven M. Hersch, Michelle Gee, Lynn D. Kramer, Sharon Cohen, Michael C. Irizarry
article en

Abstract

Weekly subcutaneous lecanemab has the potential for a prominent place in therapy by providing comparable efficacy relative to intravenous formulation with a more convenient and accessible administration by patients, caregivers or HCPs.

Alzheimer s & DementiaVol. 21(S5)
Eisai (United Kingdom) (GB), Eisai (United States) (US)
Openalex Percentile: Top 33%
Alzheimer's disease research and treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.